Clal Insurance Enterprises Holdings Ltd Increases Stock Position in Teva Pharmaceutical Industries Ltd. $TEVA

Clal Insurance Enterprises Holdings Ltd boosted its stake in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) by 18.8% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The firm owned 37,404,106 shares of the company’s stock after acquiring an additional 5,917,423 shares during the period. Teva Pharmaceutical Industries accounts for about 7.6% of Clal Insurance Enterprises Holdings Ltd’s holdings, making the stock its 3rd biggest position. Clal Insurance Enterprises Holdings Ltd’s holdings in Teva Pharmaceutical Industries were worth $1,171,378,000 as of its most recent filing with the SEC.

Several other hedge funds have also added to or reduced their stakes in the stock. Global Retirement Partners LLC raised its position in Teva Pharmaceutical Industries by 27.3% in the fourth quarter. Global Retirement Partners LLC now owns 1,360 shares of the company’s stock worth $42,000 after acquiring an additional 292 shares during the period. Banque Cantonale Vaudoise raised its position in Teva Pharmaceutical Industries by 6.3% in the fourth quarter. Banque Cantonale Vaudoise now owns 5,133 shares of the company’s stock worth $160,000 after acquiring an additional 306 shares during the period. Ethic Inc. raised its position in Teva Pharmaceutical Industries by 1.8% in the fourth quarter. Ethic Inc. now owns 18,127 shares of the company’s stock worth $566,000 after acquiring an additional 325 shares during the period. Allworth Financial LP raised its position in Teva Pharmaceutical Industries by 53.8% in the fourth quarter. Allworth Financial LP now owns 941 shares of the company’s stock worth $29,000 after acquiring an additional 329 shares during the period. Finally, EverSource Wealth Advisors LLC raised its position in Teva Pharmaceutical Industries by 51.8% in the fourth quarter. EverSource Wealth Advisors LLC now owns 1,011 shares of the company’s stock worth $32,000 after acquiring an additional 345 shares during the period. Institutional investors own 54.05% of the company’s stock.

Analyst Upgrades and Downgrades

TEVA has been the topic of several research reports. UBS Group lifted their price objective on shares of Teva Pharmaceutical Industries from $36.00 to $42.00 and gave the stock a “buy” rating in a research report on Thursday, April 30th. Barclays lifted their target price on shares of Teva Pharmaceutical Industries from $38.00 to $40.00 and gave the stock an “overweight” rating in a research note on Wednesday, May 6th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Teva Pharmaceutical Industries in a research note on Monday, April 20th. Truist Financial lifted their target price on shares of Teva Pharmaceutical Industries from $42.00 to $45.00 and gave the stock a “buy” rating in a research note on Thursday, April 30th. Finally, JPMorgan Chase & Co. lifted their target price on shares of Teva Pharmaceutical Industries from $35.00 to $40.00 and gave the stock an “overweight” rating in a research note on Thursday, April 30th. Nine investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $41.78.

Insider Activity at Teva Pharmaceutical Industries

In related news, EVP Christine Fox sold 21,258 shares of the business’s stock in a transaction that occurred on Thursday, April 30th. The shares were sold at an average price of $35.31, for a total transaction of $750,619.98. Following the completion of the transaction, the executive vice president owned 63,647 shares of the company’s stock, valued at approximately $2,247,375.57. The trade was a 25.04% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Richard Daniell sold 30,000 shares of the business’s stock in a transaction that occurred on Tuesday, May 5th. The shares were sold at an average price of $35.40, for a total transaction of $1,062,000.00. Following the transaction, the executive vice president directly owned 55,755 shares of the company’s stock, valued at approximately $1,973,727. This represents a 34.98% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 421,470 shares of company stock valued at $14,570,945 in the last quarter. 0.54% of the stock is currently owned by company insiders.

Teva Pharmaceutical Industries Price Performance

TEVA opened at $34.58 on Friday. The company has a market capitalization of $39.75 billion, a price-to-earnings ratio of 26.00, a PEG ratio of 3.53 and a beta of 0.84. The company has a quick ratio of 0.78, a current ratio of 1.01 and a debt-to-equity ratio of 1.70. The firm has a 50-day moving average price of $33.28 and a 200-day moving average price of $31.96. Teva Pharmaceutical Industries Ltd. has a twelve month low of $14.99 and a twelve month high of $37.35.

Teva Pharmaceutical Industries (NYSE:TEVA) last posted its earnings results on Tuesday, March 31st. The company reported $0.53 earnings per share for the quarter. The firm had revenue of $3.98 billion during the quarter. Teva Pharmaceutical Industries had a net margin of 9.01% and a return on equity of 43.53%. Equities analysts expect that Teva Pharmaceutical Industries Ltd. will post 2.36 EPS for the current year.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is an Israeli multinational pharmaceutical company and one of the world’s largest manufacturers of generic medicines. The company’s core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva’s product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.